Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Raises $1.45M in Second Tranche of Private Placement

NEW YORK (GenomeWeb News) – CombiMatrix said after the close of the market on Friday that it raised $1.45 million in a second tranche of its Series A Preferred Stock.

The raise is part of a private placement announced in October. Last week, CombiMatrix said that it raised $1.05 million in gross proceeds in the first tranche and that shareholders had approved the second tranche.

In the second tranche, the Irvine, Calif.-based company sold and issued 1,449.29961 shares of the Series A Stock to investors at a price of $1,000 per share. CombiMatrix issued each investor a warrant to purchase the firm's common stock initially exercisable for a number of shares of common stock equal to the number of shares of common stock issuable upon conversion at the conversion price of the stock acquired by the investor. The exercise price of the warrants issued in the second tranche is $2.364.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.